Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
Go back to Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist| Neurocrine Biosciences, Inc. (NASDAQ: NBIX) | Delayed: 146.23 -5.6 (3.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $151.83 | 52 Week High | $58.46 | |||
| Open | $152.63 | 52 Week Low | $31.25 | |||
| Day High | $152.63 | P/E | N/A | |||
| Day Low | $146.06 | EPS | $-0.69 | |||
| Volume | 2,816,257 | |||||
